# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

> **NCT01523067** · PHASE1 · COMPLETED · sponsor: **PhaseBio Pharmaceuticals Inc.** · enrollment: 68 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Vasomera (PB1046)
- **DRUG:** 0.9% Sodium Chloride

## Key facts

- **NCT ID:** NCT01523067
- **Lead sponsor:** PhaseBio Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2013-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01523067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01523067, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01523067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*